Jonathan Braverman

Biochemistry, Genetics and Molecular BiologyMedicineNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial”.

Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

Nature Medicine(2023)10.1038/s41591-022-02181-8

N/A

4.9DataRank · unranked

192 citations

Jonathan Chen, Sherry Chao, Karin Pelka, Marios Giannakis, Julian M. Hess +40 more

Dickkopf-2 regulates the stem cell marker LGR5 in colorectal cancer via HNF4α1

iScience(2021)10.1016/j.isci.2021.102411

N/A

0DataRank · unranked

20 citations

Jaekwang Jeong, Jungmin Choi, Jaechul Lim, Ravi K. Dinesh, Jonathan Braverman +14 more

Leveraging platinum-protein interactions to overcome chemoresistance

Nature Communications(2025)10.1038/s41467-025-64295-0

N/A

0DataRank · unranked

5 citations

Jonathan Braverman, George Eng, Ozen Leylek, Nicholas L. Petrone, Daniel S. Honeycutt +12 more

Improving Anticancer Activity of Doxorubicin by 4′- epi -Dehydroxyamination

ACS Medicinal Chemistry Letters(2025)10.1021/acsmedchemlett.5c00681

N/A

0DataRank · unranked

0 citations

Nicholas L. Petrone, Madeleine Maker, Brian Pallares, Trevor Leung, Allison N. Shim +5 more